C12N 2770/24171
Demonstrated in vivo effect
C12N2770/24171 (Demonstrated in vivo effect) appears on 107 US grants and 148 published applications in this corpus.
Search patents in C12N- Granted patents
- 107
- Published applications
- 148
- Assignees
- 89
- Inventors
- 237
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 2 |
| 2008 | 0 | 1 |
| 2009 | 2 | 3 |
| 2010 | 0 | 3 |
| 2011 | 3 | 5 |
| 2012 | 6 | 6 |
| 2013 | 0 | 2 |
| 2014 | 6 | 3 |
| 2015 | 7 | 8 |
| 2016 | 3 | 9 |
| 2017 | 6 | 13 |
| 2018 | 11 | 10 |
| 2019 | 9 | 18 |
| 2020 | 8 | 10 |
| 2021 | 14 | 17 |
| 2022 | 4 | 10 |
| 2023 | 10 | 8 |
| 2024 | 7 | 11 |
| 2025 | 8 | 3 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric filovirus vaccines10 Feb 2026US 12,545,709 B2Katholieke Universiteit Leuven
- Zika virus immunogenic compositions13 Jan 2026US 12,521,429 B2Loyola University of Chicago
- Multivalent virus like particle vaccines23 Dec 2025US 12,502,425 B2Texas Tech University System
- Zika virus constructs and therapeutic compositions thereof18 Nov 2025US 12,473,570 B2The Regents of the University of California
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Use of dengue vaccine in pregnant and/or breastfeeding subjects23 Apr 2026US 2026/0108594 A1Takeda Vaccines, Inc.
- Micelle comprising amphiphilic peptide, and antigen carrier nanoparticle using same12 Mar 2026US 2026/0069671 A1Rtab Co., Ltd.
- Combination therapy of oncolytic virus drugs for cancer treatment26 Feb 2026US 2026/0053873 A1Sichuan Oncocare Biopharmaceutical, Inc.
- Methods for preventing dengue and hepatitis a25 Sep 2025US 2025/0295761 A1Takeda Vaccines, Inc.
- Compositions and methods of vaccination against dengue virus in children and young adults24 Jul 2025US 2025/0235522 A1Takeda Vaccines, Inc.
Most cited
By later US patents
- Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein50US 8,715,694 B2Altravax, Inc. · 2014
- West nile virus vaccine comprising WN-80E recombinant subunit protein16US 10,039,820 B2Hawaii Biotech, Inc. · 2018
- Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use12US 9,000,141 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2015
- Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses11US 7,226,602 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2007
- Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection10US 8,337,857 B2Centre National De La Recherche Scientifique · 2012